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EDITORIAL
In this issue of the SAMJ, Fawcus et al.[1] draw attention to the epi­
demic of avoidable maternal deaths from caesarean­related haemorr­
hage in South Africa (SA). How can this epidemic be addressed?
Firstly, the most effective and cost­effective way to reduce maternal 
mortality from all causes is by preventing unintended pregnancies. 
In SA we have proved our capacity to mainstream the largest HIV 
treatment programme in the world into all levels of our health 
services. We need to do the same for family planning. In particular, 
the copper intrauterine contraceptive device (IUCD) needs to be 
made more accessible as an option. Current limited evidence suggests 
that the IUCD is more effective than injectable progestogens.[2,3] 
Health workers need training in counselling and techniques of 
inserting the IUCD after pregnancy termination, after vaginal birth 
and at caesarean section, as well as in interval insertion.
Secondly, we need to reduce unnecessary caesarean sections 
(CSs) by improving the quality of childbirth care. Drivers of the 
increasing CS rates include erosion of obstetric skills and confidence, 
and spiralling litigation, which leads to ‘defensive’, unscientific 
practices and reduces the funds available for public health services. 
Companionship during childbirth[4] has been shown to reduce 
CSs. In metropolitan areas, primary care, midwife­led childbirth 
services can be improved in terms of uptake, quality, safety and cost­
effectiveness by location on the premises of large hospitals.[5]
Thirdly, we need to ensure that women undergoing CS receive 
adequate prophylactic uterotonics. Ironically, the availability of 
intravenous access at CS has led to a preference for intravenous 
rather than intramuscular oxytocin administration, but because of 
the risk of hypotension specific to the intravenous route, the initial 
dosage has been reduced from 10 to 2.5 IU, supplemented by an 
ongoing infusion that may or may not be remembered.[6] A case may 
be made for the simplicity and certainty of the intramuscular route. 
In addition, given the increased risk and danger of haemorrhage 
in the context of CS, addition of ergometrine for women without 
contraindications, and a second dose of oxytocin after 4 hours, have 
been recommended.
As the authors point out,[1] the popularity of misoprostol has 
tended to distract attention from the more effective conventional 
uterotonics. Its formulation as a simple, inexpensive tablet may 
be assumed to be a less ‘invasive’ and therefore safer option than 
injectable uterotonics. On the contrary, misoprostol is a powerful 
prostaglandin analogue with multiple side­effects. It has a modest 
effect on blood loss after childbirth, but has not yet been shown to 
reduce the overall risk of death.[7]
What about future research? Oxytocin has the limitation of 
requiring a cold chain to maintain effectiveness. The World Health 
Organization is currently testing the effectiveness of a new, heat­
stable formulation of carbetocin.[8] More evidence is needed on the 
relative effectiveness of alternative strategies to treat haemorrhage 
when it occurs. No doubt our knowledge will increase. But to address 
the current crisis of avoidable maternal deaths, what is needed 
most are the health service infrastructure, education, workforce 
and political will to make the care already known to be effective, 
accessible to all women.
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